With Promising Data, Janssen To Ready Vaccine For Next Ebola Outbreak
Executive Summary
J&J says it will work with regulators to position its investigational Ebola Zaire vaccine for use in future outbreaks after publishing impressive Phase I prophylactic data in healthy volunteers.
You may also be interested in...
Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago
The latest drug development news and highlights from our FDA Performance Tracker.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.